PHOTOCURE ASA NK-50
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more
PHOTOCURE ASA NK-50 (PHS) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PHOTOCURE ASA NK-50 (PHS) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PHOTOCURE ASA NK-50 - Net Assets Trend (None–None)
This chart illustrates how PHOTOCURE ASA NK-50's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PHOTOCURE ASA NK-50 (None–None)
The table below shows the annual net assets of PHOTOCURE ASA NK-50 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PHOTOCURE ASA NK-50's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PHOTOCURE ASA NK-50 Competitors by Market Cap
The table below lists competitors of PHOTOCURE ASA NK-50 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
$119.95 Million |
|
West Shanghai Automotive Service Co.Ltd.
SHG:605151
|
$120.01 Million |
|
Mold-Tek Packaging Limited
NSE:MOLDTKPAC
|
$120.04 Million |
|
Guararapes Confecções S.A
SA:GUAR3
|
$120.04 Million |
|
Inozyme Pharma Inc
NASDAQ:INZY
|
$119.94 Million |
|
LaFayette Acquisition Corp. Ordinary Share
NASDAQ:LAFA
|
$119.80 Million |
|
Canton Strategic Holdings, Inc.
NASDAQ:CNTN
|
$119.80 Million |
|
Regulus Resources Inc
OTCQX:RGLSF
|
$119.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PHOTOCURE ASA NK-50's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PHOTOCURE ASA NK-50's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PHOTOCURE ASA NK-50 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PHOTOCURE ASA NK-50's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PHOTOCURE ASA NK-50 (PHS) | €- | N/A | N/A | $119.94 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |